C54.8
C54.8 — Malignant neoplasm of overlapping sites of corpus uteri
Billable / specific codeICD-10-CM
C54.8 is a billable, specific ICD-10-CM code for malignant neoplasm of overlapping sites of corpus uteri. It is valid for submission on a claim.
Risk adjustment
C54.8 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 23 Prostate, Breast, and Other Cancers and Tumors0.186 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C54.8 is named in 81 Medicare coverage policies — 81 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C54. If C54.8 is not quite right, the correct code is usually one of these.
Questions about C54.8
- Is C54.8 a billable ICD-10-CM code?
- Yes. C54.8 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C54.8 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of female genital organs (C51-C58).